Paion AG is a pharmaceutical company that focuses on developing and commercializing innovative drugs for anesthesia and critical care. The company values excellence in research and development, aiming to provide safer and more effective therapies for patients worldwide. Paion AG is committed to maintaining high ethical standards and complying with all legal and regulatory requirements. Their corporate philosophy centers around collaboration, integrity, and patient-centricity. With a passion for improving patient outcomes, Paion AG strives to create value for its shareholders, healthcare professionals, and the broader healthcare community.

Paion AG is primarily present in Germany and other European countries.

Paion AG, a renowned pharmaceutical company, has achieved notable milestones throughout its history. One significant achievement was the completion of its phase III clinical trial program for remimazolam, a promising investigational anesthetic. This milestone demonstrated the drug's efficacy and safety profile, paving the way for regulatory submissions. Paion AG has also successfully secured partnerships with major pharmaceutical companies, such as Mundipharma, to advance the development, registration, and commercialization of remimazolam. These collaborations have expanded the company's global reach and potential market opportunities. By accomplishing these milestones, Paion AG has solidified its position as a leading player in the field of anesthetics and pharmaceutical innovation.

Paion AG is a leading biopharmaceutical company based in Germany. Established in 1999, Paion specializes in the development and commercialization of innovative drugs for hospitals and medical professionals. The company focuses on anesthesia, critical care, and sedation. Paion's core product, remimazolam, is a fast-acting intravenous sedative/anesthetic agent used in surgical procedures and intensive care settings. Paion has a strong research and development pipeline, with a focus on advancing its innovative drug candidates to address unmet medical needs. With a mission to improve patient care, Paion AG continues to strive for excellence in the field of biopharmaceuticals.

The main competitors of Paion AG in the market are pharmaceutical companies such as Pfizer, AstraZeneca, and Johnson & Johnson.

Paion AG is primarily active in the pharmaceutical industry.

The business model of Paion AG revolves around research, development, and commercialization of innovative drugs for use in the fields of anesthesia, critical care, and surgery. Paion AG focuses on developing pharmacological solutions that enhance patient outcomes and improve clinical practice. The company is committed to advancing its lead product, remimazolam, which has the potential to address various medical needs by providing rapid and predictable sedation and anesthesia. Paion AG collaborates with partners and conducts clinical trials to support the approval and successful commercialization of its drug candidates. Through its business model, Paion AG aims to contribute to the advancement of patient care in relevant medical specialties.

P/E odnos Paion iznosi -0,18.

KUV kompanije Paion iznosi 0,13.

AlleAktien kvalitativni skor za Paion je 1/10.

očekivana Paion promet je 20,40 mil. EUR.

Dobit očekivana Paion je -14,30 mil. EUR.

Paion AG is a German company specializing in medications, particularly anesthetics and analgesics. The company was founded in 2000 and has since focused on the development of these drugs. Paion's core business is the development of pharmaceuticals, especially anesthetics, which relieve pain by affecting the body's nervous system. The medications are produced and distributed in collaboration with other companies. Paion is divided into three business areas: medication development, medication production and distribution, and medication sales. The company is known for the development of the drug "Remimazolam," which facilitates rapid anesthesia with reduced side effects. Paion also develops other medications such as "Boplazumab" and "Desmoteplase." The company emphasizes collaborations with other pharmaceutical companies to achieve faster and more cost-effective results. In summary, Paion focuses on the development, production, and distribution of anesthetics and pain medications, aiming to establish itself as an innovative and profitable company in the pharmaceutical industry, with the goal of improving the quality of life for pain patients worldwide.

Paion isplaćuje dividendu od 0 EUR raspoređenu preko isplata u toku godine.

Dividenda za Paion trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Paion je DE000A0B65S3.

WKN od Paion je A0B65S.

Oznaka za praćenje akcija kompanije Paion je PA8.DE.

U poslednjih 12 meseci, Paion je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Paion će verovatno isplatiti dividendu od 0 EUR.

Dividendski prinos od Paion trenutno iznosi .

Paion isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Paion je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 EUR. To odgovara dividendnom prinosu od 0 %.

Paion se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Paion od 16. 9. 2024. u iznosu od 0 EUR, morali ste da imate akciju u depou pre Ex-dana 16. 9. 2024..

Isplata poslednje dividende izvršena je 16. 9. 2024..

U godini 2023 kompanija Paion je isplatila 0 EUR kao dividende.

Dividende od Paion se isplaćuju u EUR.